Confronto
Ecnoglutide vs. Eloralintide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
nessun dato
nessun dato
Peso molecolare
nessun dato
nessun dato
Emivita
144 h
nessun dato
Sequenza
nessun dato
nessun dato
Meccanismo d'azione
Ecnoglutide
Ecnoglutide is a modified GLP-1(7-37) peptide with an alanine-to-valine substitution at position 8 and an 18-C fatty-acid conjugation at the lysine-30 side chain. It is a so-called biased agonist: at the GLP-1 receptor it preferentially induces cAMP formation while β-arrestin recruitment is reduced. In preclinical models this has been linked to lower receptor internalisation and desensitisation. GLP-1 receptor activation is mechanistically associated with enhanced glucose-dependent insulin secretion, delayed gastric emptying and satiety signalling. The fatty-acid conjugation enables weekly administration via albumin binding.
Eloralintide
Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
5
2
di cui sull'uomo
5
1
Effetti registrati
4
2
Contraddizioni aperte
0
0
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Ecnoglutide and Eloralintide?
- Ecnoglutide is classified as "Metabolico", while Eloralintide is classified as "Metabolico". Ecnoglutide: Ecnoglutide (XW003) is a long-acting, cAMP-signalling-biased GLP-1 analogue from Sciwind Biosciences. Derived from GLP-1(7-37) with an alanine-to-valine substitution at position 8, it activates the GLP-1 receptor selectively via the cAMP pathway over β-arrestin recruitment. Investigated for weight management and in type 2 diabetes. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Ecnoglutide or Eloralintide?
- The highest available evidence level is "RCT sull'uomo" for Ecnoglutide and "RCT sull'uomo" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Ecnoglutide and Eloralintide in Germany and the United States?
- Germania: Ecnoglutide — Non approvato, Eloralintide — Non approvato. Stati Uniti: Ecnoglutide — Non approvato, Eloralintide — Non approvato. These are factual summaries with source and review date on the individual pages.